Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 4/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064143 | 0.90 | CYP1A2 (0.72) | ALOX15LMNACYP1A2CYP3A4TP53 | |
| SCHEMBL10114261 | 0.87 | CYP1A2 (0.72) | ALOX15LMNACYP1A2TP53RXFP1 | |
| SCHEMBL18166670 | 0.86 | CYP1A2 (0.69) | ALOX15LMNACYP1A2CYP3A4TP53 | |
| SCHEMBL10113968 | 0.86 | TP53 (0.67) | ALOX15LMNACYP1A2TP53RXFP1 | |
| SCHEMBL10114488 | 0.85 | ALOX15 (1.00) | ALOX15LMNACYP1A2TP53RXFP1 | |
| SCHEMBL15384403 | 0.84 | LMNA (0.65) | ALOX15LMNACYP1A2TP53RXFP1 | |
| SCHEMBL10114298 | 0.83 | CYP1A2 (0.82) | ALOX15LMNACYP1A2CYP3A4TP53 | |
| SCHEMBL10114496 | 0.82 | MAPT (0.71) | ALOX15LMNACYP1A2CYP3A4TP53 | |
| SCHEMBL10113993 | 0.81 | LMNA (0.68) | ALOX15LMNACYP1A2TP53RXFP1 | |
| SCHEMBL18166606 | 0.80 | CYP1A2 (0.74) | ALOX15LMNACYP1A2CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ALOX15 148/4885LMNA 819/4885CYP1A2 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.